107 related articles for article (PubMed ID: 4061373)
1. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
[TBL] [Abstract][Full Text] [Related]
2. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of etoposide and doxorubicin in advanced head and neck cancer.
Gradishar WJ; Vokes EE; Kies MS
Med Pediatr Oncol; 1990; 18(6):487-90. PubMed ID: 2233521
[TBL] [Abstract][Full Text] [Related]
5. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gedlicka C; Kornfehl J; Turhani D; Burian M; Formanek M
Cancer Invest; 2006; 24(3):242-5. PubMed ID: 16809151
[TBL] [Abstract][Full Text] [Related]
7. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
8. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
Panduro J; Hansen M; Hansen HH
Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
[No Abstract] [Full Text] [Related]
9. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
10. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
12. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
14. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
15. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
17. A phase II trial of a new combination chemotherapy (cisplatin, bleomycin, VP-16 and methylprednisolone) in advanced recurrent squamous cell carcinoma of the head and neck.
Senra Varela A; Millan Nuñez-Cortes J; Gallurt Moreira P
Oncology; 1988; 45(6):458-60. PubMed ID: 3186156
[TBL] [Abstract][Full Text] [Related]
18. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
Tumori; 1977; 63(2):169-73. PubMed ID: 898287
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Slayton RE; Blessing JA; Homesley HD
Cancer Treat Rep; 1984 Dec; 68(12):1513-4. PubMed ID: 6509456
[No Abstract] [Full Text] [Related]
20. Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck.
Khafif A; Canfield VA; Syzek EJ; Medina JE
Am J Otolaryngol; 2003; 24(1):1-5. PubMed ID: 12579475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
